Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455331 | 1.00 | F10 (0.77) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL13738628 | 1.00 | F10 (0.77) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL13739376 | 0.88 | F10 (0.79) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL13738881 | 0.88 | F10 (0.79) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL13838775 | 0.88 | F10 (0.79) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL11934593 | 0.87 | F10 (0.59) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL7723004 | 0.87 | F10 (0.77) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL21278838 | 0.87 | F10 (0.77) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL15203246 | 0.87 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL7723895 | 0.87 | F10 (0.77) | F10ABCB11F2ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613787-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | Symed Labs Limited (IN) | 2013-07-17 | — | — | EP | claimed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | claimed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| EP-2705028-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2014-03-12 | — | — | EP | disclosed |
| EP-2613787-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | Symed Labs Limited (IN) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| WO-2013027225-A1 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | TYR, CYP1B1, AAAS | F10 4199/4885ABCB11 4685/4885F2 2038/4885 |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | CYP2C9, CYP3A5, CYP2J2 | F10 577/4885ABCB11 4493/4885F2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.